dc.contributor.author | Lord, JM | en_US |
dc.contributor.author | Veenith, T | en_US |
dc.contributor.author | Sullivan, J | en_US |
dc.contributor.author | Sharma-Oates, A | en_US |
dc.contributor.author | Richter, AG | en_US |
dc.contributor.author | Greening, NJ | en_US |
dc.contributor.author | McAuley, HJC | en_US |
dc.contributor.author | Evans, RA | en_US |
dc.contributor.author | Moss, P | en_US |
dc.contributor.author | Moore, SC | en_US |
dc.contributor.author | Turtle, L | en_US |
dc.contributor.author | Gautam, N | en_US |
dc.contributor.author | Gilani, A | en_US |
dc.contributor.author | Bajaj, M | en_US |
dc.contributor.author | Wain, LV | en_US |
dc.contributor.author | Brightling, C | en_US |
dc.contributor.author | Raman, B | en_US |
dc.contributor.author | Marks, M | en_US |
dc.contributor.author | Singapuri, A | en_US |
dc.contributor.author | Elneima, O | en_US |
dc.contributor.author | Openshaw, PJM | en_US |
dc.contributor.author | Duggal, NA | en_US |
dc.contributor.author | PHOSP-COVID Study collaborative group | en_US |
dc.contributor.author | ISARIC4C investigators | en_US |
dc.date.accessioned | 2024-03-18T12:54:14Z | |
dc.date.available | 2023-12-18 | en_US |
dc.date.issued | 2024-01-11 | en_US |
dc.identifier.issn | 1742-4933 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/95464 | |
dc.description.abstract | BACKGROUND: The striking increase in COVID-19 severity in older adults provides a clear example of immunesenescence, the age-related remodelling of the immune system. To better characterise the association between convalescent immunesenescence and acute disease severity, we determined the immune phenotype of COVID-19 survivors and non-infected controls. RESULTS: We performed detailed immune phenotyping of peripheral blood mononuclear cells isolated from 103 COVID-19 survivors 3-5 months post recovery who were classified as having had severe (n = 56; age 53.12 ± 11.30 years), moderate (n = 32; age 52.28 ± 11.43 years) or mild (n = 15; age 49.67 ± 7.30 years) disease and compared with age and sex-matched healthy adults (n = 59; age 50.49 ± 10.68 years). We assessed a broad range of immune cell phenotypes to generate a composite score, IMM-AGE, to determine the degree of immune senescence. We found increased immunesenescence features in severe COVID-19 survivors compared to controls including: a reduced frequency and number of naïve CD4 and CD8 T cells (p < 0.0001); increased frequency of EMRA CD4 (p < 0.003) and CD8 T cells (p < 0.001); a higher frequency (p < 0.0001) and absolute numbers (p < 0.001) of CD28-ve CD57+ve senescent CD4 and CD8 T cells; higher frequency (p < 0.003) and absolute numbers (p < 0.02) of PD-1 expressing exhausted CD8 T cells; a two-fold increase in Th17 polarisation (p < 0.0001); higher frequency of memory B cells (p < 0.001) and increased frequency (p < 0.0001) and numbers (p < 0.001) of CD57+ve senescent NK cells. As a result, the IMM-AGE score was significantly higher in severe COVID-19 survivors than in controls (p < 0.001). Few differences were seen for those with moderate disease and none for mild disease. Regression analysis revealed the only pre-existing variable influencing the IMM-AGE score was South Asian ethnicity ([Formula: see text] = 0.174, p = 0.043), with a major influence being disease severity ([Formula: see text] = 0.188, p = 0.01). CONCLUSIONS: Our analyses reveal a state of enhanced immune ageing in survivors of severe COVID-19 and suggest this could be related to SARS-Cov-2 infection. Our data support the rationale for trials of anti-immune ageing interventions for improving clinical outcomes in these patients with severe disease. | en_US |
dc.format.extent | 6 - ? | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Immun Ageing | en_US |
dc.rights | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecom‑ mons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. | |
dc.title | Accelarated immune ageing is associated with COVID-19 disease severity. | en_US |
dc.type | Article | |
dc.rights.holder | © The Author(s) 2024. | |
dc.identifier.doi | 10.1186/s12979-023-00406-z | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/38212801 | en_US |
pubs.issue | 1 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published online | en_US |
pubs.volume | 21 | en_US |
dcterms.dateAccepted | 2023-12-18 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |
qmul.funder | PHOSP-COVID Post-hospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes::UK Research and Innovation | en_US |